Osteoporosis visiting card references
- Royal Australian College of General Practitioners. Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age. East Melbourne: RACGP, 2017 (accessed 15 October 2018).
- Endocrinology Expert Group. Therapeutic Guidelines: Endocrinology version 5. West Melbourne: Therapeutic Guidelines Ltd, 2018 (accessed 4 October 2018).
- Bliuc D, Nguyen ND, Nguyen TV, et al. Compound risk of high mortality following osteoporotic fracture and re-fracture in elderly women and men. J Bone Miner Res 2013.
- Australian Medicines Handbook. Adelaide: AMH Pty Ltd, 2018 (accessed 1 July 2018).
- Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010;21:1943-51.
- Halpern R, Iqbal SU, Kazis LE, et al. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: A retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 2011;17:25-39.
- Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22.
- Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017;32:1291-6.
This program is funded by Theramex Australia Pty Ltd and managed by VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The content has been designed, developed and delivered by NPS MedicineWise with complete independence and editorial control and is based on best practice guidelines.